Department of Urology, Seoul National University Bundang Hospital, 166, Gumi-ro, Bundang-gu, Seongnam, Kyunggi-do 463-707, Republic of Korea.
Int J Urol. 2010 Nov;17(11):898-904. doi: 10.1111/j.1442-2042.2010.02630.x. Epub 2010 Oct 4.
To analyze the characteristics and the prognostic significance of chromophobe renal cell carcinomas (chRCC).
Data about 2981 patients with non-metastatic renal cell carcinomas (RCC) at the time of surgery were retrospectively collected from 26 institutions between 1998 and 2008. All patients had undergone partial or radical nephrectomies. Of the 2981 patients, 2602 patients with conventional RCC (cRCC) and 148 with chRCC were studied. Clinical and pathological parameters were determined in all patients. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed.
Patients with chRCC differed significantly from those with cRCC on the following parameters: younger age (P=0.026), greater female ratio (P<0.001), and larger tumor diameter (P<0.001). Both groups were alike with respect to body mass index (P=0.943), Eastern Cooperative Oncology Group performance status (P=0.163), T stage (P=0.375), and Fuhrman's grade (P=0.134). The 5-year RFS rates in patients with chRCC and cRCC were 82.7% and 83.3%, respectively (P=0.762). The 5-year CSS rates in patients with chRCC and cRCC were 88.8% and 92.2%, respectively (P=0.980). Both groups showed equivalent oncological outcomes in terms of RFS and CSS for cases stratified by T stage and Fuhrman's grade. In multivariate analysis, the histological subtype was not retained as an independent prognostic variable (RFS: P=0.893; CSS: P=0.729).
Despite being significantly different from cRCC in terms of several clinical and pathological parameters, chRCC shows equivalent oncological outcomes.
分析嫌色细胞肾细胞癌（chRCC）的特征及其预后意义。
回顾性收集了 1998 年至 2008 年间 26 家机构 2981 例手术时无转移的肾细胞癌（RCC）患者的数据。所有患者均接受了部分或根治性肾切除术。在 2981 例患者中，研究了 2602 例常规 RCC（cRCC）患者和 148 例 chRCC 患者。所有患者均确定了临床和病理参数。评估无复发生存（RFS）和癌症特异性生存（CSS）。
chRCC 患者与 cRCC 患者在以下参数上存在显著差异：年龄较小（P=0.026）、女性比例较大（P<0.001）和肿瘤直径较大（P<0.001）。两组在体重指数（P=0.943）、东部合作肿瘤组表现状态（P=0.163）、T 分期（P=0.375）和 Fuhrman 分级（P=0.134）方面相似。chRCC 和 cRCC 患者的 5 年 RFS 率分别为 82.7%和 83.3%（P=0.762）。chRCC 和 cRCC 患者的 5 年 CSS 率分别为 88.8%和 92.2%（P=0.980）。对于按 T 分期和 Fuhrman 分级分层的病例，两组在 RFS 和 CSS 方面均具有等效的肿瘤学结果。多变量分析显示，组织学亚型不是独立的预后变量（RFS：P=0.893；CSS：P=0.729）。
尽管在几个临床和病理参数方面与 cRCC 有明显不同，但 chRCC 表现出等效的肿瘤学结果。
